Oral Chinese Herbal Medicine as an Adjuvant Treatment for Chemotherapy, or Radiotherapy, Induced Myelosuppression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Oral Chinese Herbal Medicine as an Adjuvant Treatment for Chemotherapy, or Radiotherapy, Induced Myelosuppression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
复制标题
口服中草药作为化疗或放疗引起的骨髓抑制的辅助治疗：随机对照试验的系统回顾和荟萃分析
DOI：
10.1155/2017/3432750
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Huang S
中科院分区：
文献类型：
--
作者：
Hou B;Liu R;Qin Z;Luo D;Wang Q;Huang S
骨髓抑制是接受化疗或放疗的癌症患者常见的副作用。中草药（CHM）已显示出减轻骨髓抑制的希望。我们从7个没有语言限制的数据库中检索了随机对照试验（rct）。我们纳入了成人的随机对照试验，其中根据世卫组织标准测量血液学毒性，对照组接受化疗和/或放疗，治疗组给予口服中药。从数据库建立之日起至2016年10月7日，我们检索了1021篇文章。我们选择了14篇文章进行最后的分析。综合数据显示，与对照组相比，CHM显著降低了白细胞、中性粒细胞、血红蛋白和血小板的抑制率，特别是在III-IV级毒性中（白细胞：RR = 0.43, 95% CI = 0.33 - 0.56；中性粒细胞：RR = 0.39, 95% CI = 0.27-0.58；血红蛋白：RR = 0.33, 95% CI = 0.18-0.61；血小板：RR = 0.61, 95% CI = 0.39 - 0.95）。中草药作为佐剂可减轻化疗或放疗引起的骨髓抑制，降低III-IV级毒性，维持治疗剂量和治疗周期。然而，由于异质性和发表偏倚，结果应谨慎解释，并通过严格设计的高质量、大规模的多中心rct进行验证。
Myelosuppression is a common side effect in cancer patients receiving chemotherapy or radiotherapy. Chinese herbal medicine (CHM) has shown promise in alleviating myelosuppression. We searched for randomized controlled trials (RCTs) from seven databases without language restriction. We included RCTs in adults, in which hematological toxicity was measured according to WHO criteria and control group underwent chemotherapy and/or radiotherapy and the treatment group was given oral CHM. We searched 1021 articles from the date of databases inception to October 7, 2016. We selected 14 articles for the final analysis. Pooled data showed that CHM significantly decreased the suppression rate of leukocytes, neutrophils, hemoglobin, and platelets compared with the control group, particularly in grade III-IV toxicity (leukocytes: RR = 0.43, 95% CI = 0.33–0.56; neutrophils: RR = 0.39, 95% CI = 0.27–0.58; hemoglobin: RR = 0.33, 95% CI = 0.18–0.61; platelets: RR = 0.61, 95% CI = 0.39–0.95). CHM as an adjuvant can alleviate myelosuppression induced by chemotherapy or radiotherapy, reduce grade III-IV toxicity, and maintain therapeutic dose and treatment cycle. However, due to heterogeneity and publication bias, the results should be interpreted with caution and validated by conducting strictly designed multicenter RCTs of high quality and large scale.
登录
查看更多内容
DOI：
10.1007/s00432-011-0975-3
发表时间：
2011-07-01
影响因子：
3.6
作者：
Xu, Zhen Ye;Jin, Chang Juan;Cai, Xiao Yue
通讯作者：
Cai, Xiao Yue
影响因子：
2
作者：
Harbord, Roger M.;Egger, Matthias;Sterne, Jonathan A. C.
通讯作者：
Sterne, Jonathan A. C.
影响因子：
1.1
作者：
Heuer, L;Blumenberg, D
通讯作者：
Blumenberg, D
影响因子：
105.7
作者：
Higgins, JPT;Thompson, SG;Altman, DG
通讯作者：
Altman, DG
影响因子：
20.3
作者：
Lu, Huili;Zhu, Shunying;Moldenhauer, Anja
通讯作者：
Moldenhauer, Anja